1. Home
  2. GSIW vs SNTI Comparison

GSIW vs SNTI Comparison

Compare GSIW & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GSIW

Garden Stage Limited

N/A

Current Price

$30.02

Market Cap

33.5M

Sector

N/A

ML Signal

N/A

Logo Senti Biosciences Inc.

SNTI

Senti Biosciences Inc.

HOLD

Current Price

$0.98

Market Cap

29.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GSIW
SNTI
Founded
2016
2016
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
33.5M
29.8M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
GSIW
SNTI
Price
$30.02
$0.98
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$8.50
AVG Volume (30 Days)
2.2K
160.0K
Earning Date
08-04-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
77.31
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.05
$0.77
52 Week High
$36.90
$3.88

Technical Indicators

Market Signals
Indicator
GSIW
SNTI
Relative Strength Index (RSI) 65.93 51.06
Support Level $0.11 $0.81
Resistance Level $32.25 $0.99
Average True Range (ATR) 0.79 0.08
MACD -0.62 -0.01
Stochastic Oscillator 31.93 40.30

Price Performance

Historical Comparison
GSIW
SNTI

About GSIW Garden Stage Limited

Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong; and I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.

About SNTI Senti Biosciences Inc.

Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).

Share on Social Networks: